Back to journals
Academic Journal

Addiction

10 Papers Indexed in Blossom

Published Papers

Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Open Accessindividual

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial

In an open‑label Phase IIa trial (n-12), a single 10 mg intranasal dose of 5‑MeO‑DMT (BPL‑003) given alongside a 10‑week relapse‑prevention CBT programme was acceptable in safety and tolerability in people with moderate–severe alcohol use disorder. Over 12 weeks, participants showed large improvements in drinking (mean abstinent days rose from 33.2% to 80.8% and heavy drinking days fell from 56.2% to 13.2%), providing preliminary evidence of efficacy and supporting larger controlled trials.

Published
Journal
Addiction
Authors
Marsden, J., Kelleher, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Roberts, C., Rucker, J. J., Scott, G., Saeger, I., Small, F., Seynaeve, M.
Open Accessindividual

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

In a single‑arm, open‑label pilot of 15 people with methamphetamine use disorder, outpatient psilocybin‑assisted psychotherapy (single 25 mg oral dose with preparatory and integration sessions) was feasible and well tolerated with no serious adverse events, and was associated with reductions in self‑reported methamphetamine use and craving at 28 and 90 days; a larger randomised trial is required to confirm efficacy and safety.

Published
Journal
Addiction
Authors
Knock, E., Siefried, K. J., Gill Bedi, |., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., Brett, J., Bedi, G.
Paywallindividual

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

In this double‑blind, randomised pilot trial of recently detoxified patients with severe alcohol use disorder and comorbid depression, two 25 mg psilocybin‑assisted psychotherapy sessions (versus 1 mg control) were feasible, acceptable and safe. At 12 weeks the 25 mg group showed higher abstinence (55% vs 11%) and significant reductions in percent drinking days and craving frequency, although blinding was imperfect and the study was small and preliminary.

Published
Journal
Addiction
Authors
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., Sergent, F.
Open Accessindividual

Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021

In a longitudinal US cohort of 11,304 young adults aged 19–30 surveyed 2018–2021, past‑year LSD use remained stable (≈3.7% to 4.2%) while non‑LSD hallucinogen use (e.g. psilocybin) roughly doubled from 3.4% to 6.6%. Use was more likely among males, white participants and those from higher socio‑economic backgrounds, and less likely among Black participants and those without a college‑educated parent.

Published
Journal
Addiction
Authors
Keyes, K. M., Patrick, M. E.
Open Accessmeta

Repurposing ketamine to treat cocaine use disorder: Integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration, and mechanism of action analyses

This analysis of ketamine data (3800 patients who received ketamine for anaesthesia, and the same number of controls) suggest that ketamine may be useful for treating cocaine use disorder (CUD).

Published
Journal
Addiction
Authors
Gao, Z., Winhusen, |. T. J., Gorenflo, |. M., Ghitza, U. E., Davis, P. B., Kaelber, D. C., Xu, R., Winhusen, T. J.

Quick Facts

Papers Indexed
10
h-Index
224
Open Access
No
Publisher
Society for the Study of Addiction
Country
United Kingdom
Website
Visit